DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ., USA), to initiate a Phase I combination trial of PMC-309, a novel anti-VISTA (V-domain...

Related Keywords

Australia , United States , Daejeon , Taejon Gwangyoksi , South Korea , Jin San Yoo , Linkedin , Business Development Team , Ir Pr Team , Pharmabcine Inc , Merck Co Inc , Youtube , Merck Sharp Dohme , Prnewswire Pharmabcine Inc , Triple Negative Breast Cancer , Merck Sharp , V Domain Ig Suppressor , Myeloid Derived Suppressor Cells , Clinical Trial Application , Tumor Microenvironment , Age Related Macular Degeneration ,